An investigational drug has prolonged survival in patients with a rare and deadly form of acute myeloid leukemia (AML).
An investigational drug has prolonged survival for patients with acute myeloid leukemia (AML) who have a genetic mutation called FMS-like internal tandem duplications (FLT3-ITD). The results of the phase 3 trial, which was led by The University of Texas MD Anderson Cancer Center, were presented at the European Hematology Society’s 23rd Congress.1
AML with the FLT3-ITD mutation is a rare and deadly form of the disease that affects approximately one-third of patients with AML. These patients present with more aggressive disease and are more likely to relapse after remission.2
So far, quizartinib, a second-generation FLT3 inhibitor, has shown promising activity. The new findings of the QUANTUM-R study presented at the European Hematology Society have confirmed the efficacy and safety of the treatment, as well as the value of targeting FLT3-ITD with the agent, which is a small molecule receptor tyrosine kinase inhibitor.
“Currently, there are no approved targeted therapies for patients with relapsed FLT3-ITD-associated AML, which represent a significant unmet medical need,” Jorge Cortes, MD, deputy chair and professor of Leukemia at MD Anderson, as well as the lead investigator of the QUANTUM-R study, said in a statement. “Our findings demonstrated that patients on quizartinib alone had an estimated overall survival of 27% after 52 weeks of treatment compared to 20% for patients on standard chemotherapies.”
The study enrolled adult patients who either had refractory AML or who had relapsed 6 months or less following complete remission. A total of 367 patients were randomized 2:1 to receive either quizartinib once daily or the investigator’s choice of several chemotherapy options (low-dose cytarabine; the combination of mitoxantrone, etoposide, and cytarabine; or the combination of fludarabine, cytarabine, and idarubicin).
The median overall survival was 27 weeks for patients treated with quizartinib and 20.4 weeks for patients treated with chemotherapy. Treatment-emergent adverse events were comparable between the 2 arms.
“These pivotal data confirm that targeting FLT3-IT with this potent new therapy may be of significant clinical value,” said Cortes. “These results represent the first positive phase 3 trial to demonstrate improved overall survival in patients with AML-associated FLT3-ITD.”
References
1. Cortes J, Khaled S, Martinelli G, et al. Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication—mutated (MUT) relapsed/refractor AML in the phase 3, randomized, controlled QUANTUM-R trial. Presented at the 23rd Congress of the European Hematology Association. June 16, 2018; Stockholm, Sweden.
2. Fathi AT, Chen YB. Treatment of FLT3-ITD acute myeloid leukemia. Am J Blood Res. 2011;1(2):175-189. PMID: 22432079.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More